Performance of novel low-density lipoprotein-cholesterol calculation methods in predicting clinical and subclinical atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis

Jing Cao, Alan T. Remaley, Weihua Guan, Sridevi Devaraj, Michael Y. Tsai

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

BACKGROUND AND AIMS: This study examined the performance of two novel low-density lipoprotein-cholesterol (LDL-C) calculations, LDL Martin and LDL Sampson, on predicting atherosclerotic cardiovascular diseases (ASCVD) risk compared to traditional LDL Friedewald according to the 2018 American Heart Association/American College of Cardiology (AHA/ACC) primary prevention guidelines.

METHODS: A total of 6701 randomly recruited Multi-Ethnic Study of Atherosclerosis (MESA) participants free of ASCVD at baseline were followed for ASCVD during a median of 13.9 years and for subclinical ASCVD-coronary artery calcium (CAC) during a median of 12.5 years. Prevalence of borderline high triglyceride (≥1.7 mmol/L) was 15.2% and was at 13.5% for high triglyceride (≥2.3 mmol/L).

RESULTS: Applying the criteria of LDL-C<1.8 mmol/L in 40-75 year olds without diabetes mellitus to be exempt from risk discussion, LDL Martin and LDL Sampson classified less individuals in this category than LDL Friedewald (p < 0.001), both had 20 individuals with ASCVD, versus 22 by LDL Friedewald. Positive CAC in the discussion-exempt group were over 38% higher (p < 0.001) when classified by LDL Friedewald than by LDL Martin or LDL Sampson. Individuals with LDL-C≥4.9 mmol/L are recommended to high-intensity statin therapy by the AHA/ACC guidelines. The LDL Friedewald≥4.9 mmol/L group had 20 ASCVD events, versus 21 in LDL Martin and 22 in LDL Sampson group.

CONCLUSIONS: In a multi-ethnic USA population, LDL Martin and LDL Sampson did not over- or under-estimate ASCVD risk compared to LDL Friedewald in primary prevention according to AHA/ACC guidelines, while LDL Friedewald under-estimated subclinical ASCVD risk in the low-risk population. These findings support the replacement of LDL Friedewald by LDL Martin or LDL Sampson for lipid screen in the general population.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalAtherosclerosis
Volume327
DOIs
StatePublished - Jun 2021

Bibliographical note

Funding Information:
This research was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from National Center for Research Resources .

Publisher Copyright:
© 2021 Elsevier B.V.

Keywords

  • Cardiovascular disease risk
  • LDL-C Calculation
  • Low-density lipoprotein cholesterol
  • Cardiovascular Diseases
  • Risk Assessment
  • United States
  • Humans
  • Risk Factors
  • Atherosclerosis
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Performance of novel low-density lipoprotein-cholesterol calculation methods in predicting clinical and subclinical atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis'. Together they form a unique fingerprint.

Cite this